iForumRx.org

How Long Is Long Enough? Extending OAC After Unprovoked PE

The recommended treatment duration for a first episode of unprovoked venous thromboembolism (VTE) is, at a minimum, 3 months with extended anticoagulation favored for those who are not at high risk for bleeding.  However, the optimal duration of anticoagulation therapy remains unknown. The Prolonged Anticoagulation Treatment for a First Episode of Idiopathic Pulmonary Embolism (PADIS-PE) study examines this question but, most importantly, provides insights about patient outcomes after anticoagulation treatment is discontinued

PCSK9 Inhibitors: Blockbusters or Bust?

Two new mAbs, alirocumab and evolocumab, have been approved to treat elevated cholesterol when added to maximally tolerated statin therapy in patients with familial hypercholesterolemia or history of atherosclerotic cardiovascular disease (ASCVD). This new class of drugs, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, is considered to be the biggest breakthrough in cholesterol treatment since statins were approved 3 decades ago. But are they worth it?

CVD Risk Scores - Are They Accurate?

How well do cardiovascular disease risk calculators really perform?  Do they over or underestimate risk?  Should we rely on them to make treatment decisions?

Intensive Antiplatelet Therapy - Is Extended Therapy Worth It?

Our guests - Dr. Cortney Mospan and Dr. Augustus (Rob) Hough - critically examine the results of the DAPT and PEGASUS-TIMI 54 studies and explain how the results should be applied in practice.

Potential Uses of Niacin: Flushing Out The Results of HPS2-THRIVE

Guidelines promote the use of statins as first line therapy to prevent atherosclerotic cardiovascular disease events. Does adding niacin to statin treatment reduce residual risk?